Recent Publications

Effects of Therapeutic Antibiotic Exposure on the Oropharyngeal and Fecal Microbiota in Infants with Cystic Fibrosis. Hayden HS, Nelson MT, Ross SE, Verster AJ, Bouzek DC, Eng A, Waalkes A, Penewit K, Kopp BT, Siracusa C, Rock MJ, Salipante SJ, Hoffman LR, Sanders DB. Pediatr Pulmonol. 2025 Mar;60(3):e71024. doi: 10.1002/ppul.71024. PMID: 40042126. PMCID: PMC11881217.

The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol. Liu CM, Fischer JL, Zemanick ET, Woods JC, Markarian KK, Fain SB, Froh D, Heltshe SL, Hoffman LR, Humphries SM, Kramer EL, Ode KL, Lewis M, Li DA, Mata J, Milla SS, Niedbalski PJ, Sawatzky BD, Sim MS, Sullivan JS, Trout AT, Goss CH, Taylor-Cousar JL, Beswick DM. ERJ Open Res. 2025 Jan 13;11(1):00137-2024. doi: 10.1183/23120541.00137-2024. eCollection 2025 Jan. PMID: 39811548. PMCID: PMC11726580.

Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs. Gharib SA, Vemireddy R, Castillo JJ, Fountaine BS, Bammler TK, MacDonald JW, Hull-Meichle RL, Zraika S. Sci Rep. 2024 Oct 28;14(1):25689. doi: 10.1038/s41598-024-76722-1. PMID: 39463434. PMCID: PMC11514218.

Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death. Gonsalves LJ, Tran A, Gardiner T, Freeman T, Dutta A, Miller CJ, McNamara S, Waalkes A, Long DR, Salipante SJ, Hoffman LR, Wolter DJ. mBio. 2024 Nov 13;15(11):e0163424. doi: 10.1128/mbio.01634-24. Epub 2024 Oct 24. PMID: 39445807. PMCID: PMC11559000.

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. Morgan SJ, Coulter E, Betts HL, Solomon GM, Clancy JP, Rowe SM, Nichols DP, Singh PK; PROMISE-Micro Study Group. J Clin Invest. 2024 Sep 5;134(20):e184171. doi: 10.1172/JCI184171. PMID: 39235967. PMCID: PMC11473140. No abstract available.